Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO Italy 2020 | New insights in the biology of myeloproliferative neoplasms

Anna Rita Migliaccio • 17 Sep 2020
SOHO Italy 2020
Myelofibrosis Myeloproliferative Neoplasms Ruxolitinib

Anna Rita Migliaccio, PhD, University of Bologna, Bologna, Italy, discusses novel insights into the pathogenesis of myelofibrosis and the changes involved in the development of myeloproliferative neoplasms from benign forms of disease. Dr Migliaccio outlines the use of ruxolitinib, which improves symptoms of myelofibrosis but highlights the need for curative therapies, including treatments targeting TGF-beta and p-selectin which have shown in mouse models to have curative effects. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Anna Rita Migliaccio

3:19
Finding novel targets for myelofibrosis from animal models
Anna Rita Migliaccio • 9 Sep 2020

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals